Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	August 11, 2016
Length of Meeting:	2 hours and 0 minutes
Location of Meeting:	DMAS Board Room 13th Floor

Members Present:

Randy Ferrance, MD, Chair	Bill Rock, PharmD, Vice Chair
Avtar Dhillon, MD	Denese Gomes, NP
Seth Brant, MD	Sandra Dawson, RPh
Wendy Nash, PharmD	Michele Thomas, PharmD

Members Not Present:
Kathryn Reid, PhD
Jonathan Evans, MD

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Rachel Cain, PharmD
Katherine Neuhausen, MD, MPH, Chief Medical Officer
Dacia Henry, Program Integrity

Contractors:
MaryAnn McNeil, RPh, Clinical Pharmacy Manager, Xerox
Tina Carter, CPhT, Xerox

Vendors:
Debbie Moody, RPh, Magellan Health Services

Visitors:
Beth Pegram, Vertex
Ken Jennings, BMS
Alain Porté, Walgreens
Chris Fields, Lundbeck
Mickey Minnik, Otsuka
Paul Hodgkins, Vertex

Call to Order and Introductions

Dr. Ferrence called the meeting to order at 2:02pm. Rachel Cain introduced the new Medical Director, Dr. Katherine Neuhausen.

Minutes – May 12, 2016

Meeting minutes were reviewed and approved.

NEW Drugs

Descovy® (emtricitabine and tenofovir alafenamide) - M. McNeil presented the drug information and service authorization criteria recommendations. The motion was made to table this review until the November 2016 DUR Board meeting and bring Truvada service authorization criteria for final recommendations.

Epclusa® (sofosbuvir and velpatasvir) – Removed from DUR Board agenda and not reviewed by Board. Epclusa® will be reviewed at the next scheduled Pharmacy and Therapeutics Committee (P&T) meeting.

Ocaliva® (obeticholic acid) - M. McNeil presented the drug information. No action required.

Cabometyx® (cabozantinib) - M. McNeil presented the drug information and service authorization criteria recommendations for Cabometyx. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

New Drugs: Physicians-administered - M. McNeil presented the drug information for New Physician-administered Drugs. The motion was made to accept the criteria as written with the exception of Kybella® (deoxycholic acid) Injection – classified as cosmetic, medical services. The Board seconded and approved the criteria.

PDL Eligible Drugs reviewed - M. McNeil presented the drug information for PDL Eligible Drugs. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Service Authorizations – No updates needed.

Topics for Discussion

Analysis of Compounded Prescriptions – M. McNeil presented the data findings requested by the DUR Board at the May meeting. The motion was made to deny Ketamine at POS. The motion was seconded and approved by the board with a request to report on denials and appeals for discussion at the November meeting. M. McNeil presented the pricing comparison of ingredients and vehicles by manufacturer for compound medication claims. The Board discussed covering active drug(s) only and not the cost of the vehicles. The Board requested a repeat data pull for the November meeting with additional information – specialty description, demographics, amounts >$500 for orals and topicals, breakdown by Long Term Care (LTC), breakdown by pediatric orals and liquids. Other requests: letter to prescribers for evidence base, draft letter to PCCA for evidence cost based studies, M. McNeil to follow up with Xerox auditing of Fraud and Abuse for Compounded medications, M. McNeil to research other

States' processes and invite Barbara Exum from the VCU Compounding Department to attend the next DUR Board meeting for input.

Dose Optimization – M. McNeil presented utilization reports and cost analysis for the antipsychotic drug class of medications. The recommended quantity limits are based on FDA approved dosage indications. The antidepressant class was also evaluated and not found to be cost effective. Xerox will continue to review other classes of medications. The motion was made to accept approval criteria for the drugs specified in the antipsychotic drug class. The Board seconded and approved the criteria.

Pediatric Narcotic Utilization – M. McNeil presented pediatric narcotic utilization reports for a period of 6 months. Based on the small number of claims submitted, Xerox recommends that the pediatric population continues to be excluded for narcotic quantity edits and the 10 day limit on short acting opioids as per current DMAS policy. The Board requested a repeat data pull for the November meeting with additional information as follows: demographics by regions, dentists vs prescribers and diagnosis.

Morphine Equivalent Dosing for Narcotics – Tabled until the November DUR Board meeting.

Concurrent Use of Buprenorphine with Opioids – Tabled until the November DUR Board meeting.

DUR Quarterly Newsletter – Tabled until the November DUR Board meeting.

Reports

ProDUR and RetroDUR- Tabled until the November DUR Board meeting.

Utilization Analysis Reports- Tabled until the November DUR Board meeting.

Top Diagnoses by Age- Tabled until the November DUR Board meeting.

AAP Report- Tabled until the November DUR Board meeting.

By-Laws – Reviewed by DUR Board. The motion was made to accept the By-Laws "as is". The Board seconded and approved the motion. The motion was made for Randy Ferrance, MD to remain as chairperson for 2016 - 2017. The Board seconded and approved the motion.

Next DUR Board meeting scheduled for November 10th 2016. (review tabled items from the August meeting, board requested no New Topics for the November meeting)

Other Business -The Board motioned and approved the 2017 DUR Board meeting calendar as follows:

February 9th, May 11th, August 10th and November 9th.

Beer's List Criteria – Confirmed by policy no longer a required report for the DUR Board.

Meeting was adjourned at 4:02 pm.